A meta-analysis of 18F-Fluoride positron emission tomography for assessment of metastatic bone tumor

Annals of Nuclear Medicine

Volumn 24, Issue 7, 2010, Pages 523-531

  Tateishi, Ukihide ^a   Morita, Satoshi ^a   Taguri, Masataka ^a   Shizukuishi, Kazuya ^a   Minamimoto, Ryogo ^a   Kawaguchi, Masashi ^a   Murano, Takeshi ^b   Terauchi, Takashi ^b   Inoue, Tomio ^a   Kim, E Edmund ^c  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

^b NATIONAL CANCER CENTER   (Japan)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

18F Fluoride; PET; PET CT

Indexed keywords

FLUORINE 18;

ARTICLE; BONE METASTASIS; BONE SCINTISCANNING; CANCER PATIENT; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CLINICAL TRIAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; HUMAN; INTERMETHOD COMPARISON; META ANALYSIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION DOSE; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW;

BONE NEOPLASMS; FLUORIDES; FLUORINE RADIOISOTOPES; HUMANS; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 78149360688     PISSN: 09147187     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12149-010-0393-7     Document Type: Article

References (22)

1. Ghanem N, Uhl M, Brink I, Schäfer O, Kelly T, Moser E, et al. Diagnostic value of MRI in comparison to scintigraphy, PET, MS-CT and PET/CT for the detection of metastases of bone. Eur J Radiol. 2005;55:41-55.
2. Goudarzi B, Kishimoto R, Komatsu S, Ishikawa H, Yoshikawa K, Kandatsu S, et al. Detection of bone metastases using diffusion weighted magnetic resonance imaging: comparison with 11C-methionine PET and bone scintigraphy. Magn Reson Imaging. 2010 (in press).
3. Vallabhajosula S. (18) F-labeled positron emission tomographic radiopharmaceuticals in oncology: an overview of radiochemistry and mechanisms of tumor localization. Semin Nucl Med. 2007;37:400-19.
4. Cook GJ, Fogelman I. Detection of bone metastases in cancer patients by 18F-fluoride and 18F-fluorodeoxyglucose positron emission tomography. Q J Nucl Med. 2001;45:47-52.
5. Grant FD, Fahey FH, Packard AB, Davis RT, Alavi A, Treves ST. Skeletal PET with 18F-fluoride: applying new technology to an old tracer. J Nucl Med. 2008;49:68-78.
6. 18F-Fluoride positron emission tomography and positron emission tomography/computed tomography. Semin Nucl Med. 2007;37:462-9.
7. ImPACT. CT patient dosimetry Excel spreadsheet (version 0.99v, 17 June 2004). http://www.impactscan.org/.
8. Murano T, Tateishi U, Iinuma T, Shimada N, Daisaki H, Terauchi T, et al. Evaluation of the risk of radiation exposure from new 18FDG PET/CT plans versus conventional x-ray plans in patients with pediatric cancers. Ann Nucl Med. 2010;24(4):261-7.
9. Jones D, Shrimpton P. NRPB-SR250: normalised organ doses for X-ray computed tomography calculated using Monte Carlo techniques. National Radiological Protection Board. 1993.
10. International Commission on Radiological Protection. 1990 recommendations of the International Commission on Radiological Protection. ICRP publication 60. Annals of the ICRP, vol 21, issue 1-3. Oxford: Elsevier; 1991.
11. Hetzel M, Arslandemir C, König HH, Buck AK, Nüssle K, Glatting G, et al. F-18 NaF PET for detection of bone metastases in lung cancer: accuracy, cost-effectiveness, and impact on patient management. J Bone Miner Res. 2003;18:2206-14.
12. Hoh CK, Hawkins RA, Dahlbom M, Glaspy JA, Seeger LL, Choi Y, et al. Whole body skeletal imaging with [18F]fluoride ion and PET. J Comput Assist Tomogr. 1993;17:34-41.
13. Hoegerle S, Juengling F, Otte A, Altehoefer C, Moser EA, Nitzsche EU. Combined FDG and [F-18]fluoride whole-body PET: a feasible two-in-one approach to cancer imaging? Radiology. 1998;209:253-8.
14. Schirrmeister H, Guhlmann A, Kotzerke J, Santjohanser C, Kühn T, Kreienberg R, et al. Early detection and accurate description of extent of metastatic bone disease in breast cancer with fluoride ion and positron emission tomography. J Clin Oncol. 1999;17:2381-9.
15. Schirrmeister H, Guhlmann A, Elsner K, Kotzerke J, Glatting G, Rentschler M, et al. Sensitivity in detecting osseous lesions depends on anatomic localization: planar bone scintigraphy versus 18F PET. J Nucl Med. 1999;40:1623-9.
16. Schirrmeister H, Glatting G, Hetzel J, Nüssle K, Arslandemir C, Buck AK, et al. Prospective evaluation of the clinical value of planar bone scans, SPECT, and (18) F-labeled NaF PET in newly diagnosed lung cancer. J Nucl Med. 2001;42:1800-4.
17. Even-Sapir E, Metser U, Flusser G, Kollender Y, Lerman H, Lievshitz G, et al. Assessment of malignant skeletal disease: initial experience with 18F-fluoride PET/CT and comparison between 18F-fluoride PET and 18F-fluoride PET/CT. J Nucl Med. 2004;45:272-8.
18. Even-Sapir E, Metser U, Mishani E, Lievshitz G, Lerman H, Leibovitch I. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single-and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. J Nucl Med. 2006;47:287-97.
19. Beheshti M, Vali R, Waldenberger P, Fitz F, Nader M, Loidl W, et al. Detection of bone metastases in patients with prostate cancer by 18F fluorocholine and 18F fluoride PET-CT: a comparative study. Eur J Nucl Med Mol Imaging. 2008;35:1766-74.
20. Kawaguchi M, Tateishi U, Shizukuishi K, Suzuki A, Inoue T. F-18 fluoride uptake in bone metastasis: morphologic and metabolic analysis on integrated PET/CT. Ann Nucl Med. 2010;24(4):241-7.
21. Iagaru A, Mittra E, Yaghoubi SS, Dick DW, Quon A, Goris ML, et al. Novel strategy for a cocktail 18F-fluoride and 18F-FDG PET/CT scan for evaluation of malignancy: results of the pilotphase study. J Nucl Med. 2009;50:501-5.
22. Nemeth AJ, Henson JW, Mullins ME, Gonzalez RG, Shaefer PW. Improved detection of skull metastasis with diffusion-weighted MR imaging. Am J Neuroradiol. 2007;28:1088-92.